New Zealand Oncology Research Grant **August 30, 2023**

As part of our ongoing program to connect with cancer researchers, below describes a Research Grant Program, planned for August 30, 2023 to October 31, 2023.

Approach:

- One grant will be awarded
- The grant winner must submit 12 samples to Grafton Clinical Genomics, University of Auckland. Samples will be processed by Grafton Clinical Genomics using QIAGEN AllPrep kits and prepared into sequencing libraries using the QIAseq Multimodal HT Pan-Cancer Panel. Sequencing will be carried out by Grafton Clinical Genomics utilizing the MGI DNBSEQ-G400 Sequencing platform.
- The grant winner will receive sequencing data which can be processed with a QIAGEN Digital Insights workflow or the winner may opt to process the data with their own workflow.
- Applications are open to all New Zealand research scientists, principal investigators or post-doctoral scientists.
- Applicants must be over the age of 18 as of October 31, 2023.
- Submissions will be reviewed by Ivon Harliwong, Sales Development Manager, Clinical Genomics, QIAGEN, and Emma Liu, Marketing Manager, MGI New Zealand, for completeness, scientific interest, and feasibility.
- Applications must be submitted by 5 p.m. NZST, 31 October 2023.
- Grant winner must submit their samples to Grafton Clinical Genomics by 31 March 2024.
- If the grant winner submits their work performed to any publication, this must first be submitted to QIAGEN/MGI for review.
- The winner will be announced by February 29, 2024.
- Applicants must include the following information in their submission
    - Full name, employing institute, email address and phone number
    - Project title, project overview (abstract and objective)
    - Existing method/workflow
    - Identify the research objective
    - Identify what they plan to do and how would QIAGEN AllPrep kits and the QIAseq Multimodal HT Pan-Cancer Panel be used

- Number of publications in the past two years (please list publication)

- Consultation or advice about the NZ Oncology research grant is available by emailing ivon.harliwong@qiagen.com with the subject line: NZ Oncology Research Grant.

- The successful applicant agrees to have their name and the purpose of the grant made public.

- Data generated from this grant project may be used in application notes generated by QIAGEN and/or MGI.

- The winner may be invited to talk about their research for QIAGEN, MGI and GCG at seminars and/or conferences in 2024.

- Grant winner must sign the “Research Grant Acceptance Form”.

Official Rules

QIAGEN will provide the Research Grant only to the employer of the winning applicant. The person submitting the application (the “Applicant”) is therefore entering on behalf of their employer, which will be the recipient of the Research Grant (the “Grant Recipient”). By submitting an application for a Research Grant, the Applicant certifies that he or she has obtained any permissions required from the Grant Recipient to submit such application on the Grant Recipient’s behalf and is not violating any policies of the Grant Recipient in so doing.

This program is void where prohibited by law. Individuals or entities classified as healthcare professionals or healthcare organizations under any applicable laws or industry codes of ethics may not participate in this program. The Applicant shall comply with all applicable laws and regulations to use the Grant, including but not limited to laws of intellectual property, data privacy, anti-bribery, anti-corruption and anti-money laundering.

All applications must be submitted in the English language. One entry per person. Winning applications will be chosen by QIAGEN based on completeness, scientific interest, and geographic location, as determined by QIAGEN at its sole discretion.

All taxes, including, without limitation, federal, state, and local taxes on or in connection with the prize are the sole responsibility of the winning entry. No cash award alternative to the Research Grant will be awarded and the Research Grant is not transferable. QIAGEN reserves the right to substitute any award of equal or greater value in its sole discretion. In the event a winner cannot receive his/her award for any reason, the award shall be awarded to an alternate winner.

QIAGEN reserves the right to cancel, suspend and/or modify the Research Grant program in its sole discretion. By participating in the Research Grant program, entrants agree to release and hold harmless QIAGEN and MGI and its affiliates from and against any claim or cause of action arising out of participation in the Research Grant program, including any errors in the administration of the Research Grant, printing errors, and technical errors, and the Applicant and Grant Recipient agree to release and

hold harmless QIAGEN and MGI and its affiliates as well from receipt or use of any Research Grant awarded, and further agree to the disclosure of their respective names in connection with QIAGEN's and MGI's promotion of the Research Grant program.

QIAGEN reserves the right to exclude participants, at any time and without notice, who technically tamper with the contest, the selection process or otherwise, to oppose these terms and conditions. In case of a dispute regarding the identity of the person submitting an online entry, the entry will be deemed to be submitted by the person in whose name the e-mail account is registered. If a certain name is suggested by more than one person, the entry will be deemed to be suggested according to the date of the suggestion being registered, the first person to submit the suggestion will, therefore, be credited with it.

Return of any award notification as undeliverable will result in forfeiture of the award. Legal recourse is excluded. QIAGEN, its officers, directors, affiliates, subsidiaries, agencies, agents and representatives and their respective employees are not responsible and shall not be liable for: (a) electronic, hardware or software program, network, internet or computer malfunctions, failures or difficulties of any kind, including without limitation server malfunctions or by any error (human or otherwise) which may occur in the processing of applications; or (b) any condition caused by events beyond the control of QIAGEN that may cause the application and award process to be disrupted or corrupted. Any attempt by an entrant to deliberately damage any website or undermine the legitimate operation of the award program may be a violation of criminal and civil laws. Should such an attempt be made, QIAGEN reserves the right to seek damages from such person to the extent permitted by law.

Data processing. QIAGEN is committed to protecting your privacy. When we process personal data, we observe the rules laid down in the applicable data protection laws, including but not limited to General Data Protection Regulation (EU) 2016/679 and California Consumer Privacy Act. Further details can be found in our Privacy Policy. If personal data is transferred outside the EU/EEA, we will ensure that appropriate contractual measures (e.g., using standard contractual clauses of the EU Commission) are applied to the transfer, the transfer is lawful and that the processing and confidentiality are in compliance with the applicable laws.

Participants consent to their identity being revealed in announcements via the company's internal communications channels. For further information, please refer to QIAGEN's Privacy Policy available at www.qiagen.com.

These Official Rules are governed by, and must be construed in accordance with, the laws of Maryland. Entrants agree that all disputes arising from or in connection with this Research Grant must be heard in a state or federal court of Maryland.

Sponsor: The Research Grant is sponsored by QIAGEN Limited, Level 2, 4 Gillies Avenue, Newmarket 1023 Auckland, New Zealand.